عربي
English
Quick links
Related sites
Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Login area | Sign up
Forgot your password? Click here
Let us help you
Read about the latest topics.
Download the new version of the MOPH app 
for the latest updates on Coronavirus
 
Be Responsible
#Raise your voice
Send us any Fraudulent Action or Enquiry so we can ALL contribute to make a Difference

Strengthening Lebanon's COVID-19 Response Project in Collaboration with the World Bank


Due to the unmet need for vaccines and the financial limitation of the GOL to meet the increasing health care needs, the “Strengthening Lebanon’s COVID-19 Response Project” will finance further purchase and deployment of equitable COVID-19 vaccines and needed supplies and activities to support the GOL COVID-19 response.

Strengthening Lebanon’s COVID-19 Response Project has a budget of US$29M and duration of two years and comprises the following components:
•     Component 1 – Procurement of COVID-19 vaccines and deployment:
This component will support the purchase of COVID-19 vaccines and related deployment activities.

•     Component 2- COVID-19 prevention, detection and case management:
 This component will support other COVID-19 prevention, detection and case management activities.

•     Component 3 – System Strengthening, Monitoring and Management: This component will finance the project management unit, which includes at least: (i) financial management officers (FM), (ii) procurement and due diligence team; (iii) environmental and social officers; (iv) monitoring and evaluation officers and vi) Coordination. In addition, the component will support activities aimed at strengthening the health system in critical areas such as information systems, public health surveillance capacity, supply management/logistics, and expansion of primary health care settings.


Strengthening Lebanon’s Covid-19 Response (P178587)- Labor Management Procedures (LMP)- September 2022
Environmental and Social Management Framework (ESMF)- May 2022
Environmental and Social Commitment- (ESCP)- May 2022
Stakeholder Engagement Plan (SEP)- May 2022
    1
    2
    3
    4
    5
    6
    ...
    10
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
All
ATC Name B/G Ingredients Dosage Form Price
L04AX04 LENALIDOMIDE SPC G Lenalidomide - 5mg 5mg Capsule, hard 71,647,217 L.L
L04AX04 LENOMA G Lenalidomide - 5mg 5mg Capsule, hard 68,908,116 L.L
L04AX04 LENALIDOMIDE SPC G Lenalidomide - 10mg 10mg Capsule, hard 75,120,146 L.L
L04AX04 LENOMA G Lenalidomide - 10mg 10mg Capsule, hard 14,449,637 L.L
C10BA06 LIPOCOMB B Rosuvastatin (calcium) - 10mg, Ezetimibe - 10mg Capsule, hard 2,701,123 L.L
C10BA06 LIPOCOMB B Rosuvastatin (calcium) - 20mg, Ezetimibe - 10mg Capsule, hard 2,701,123 L.L
L04AX04 LENOMA G Lenalidomide - 15mg 15mg Capsule, hard 15,241,884 L.L
L04AX04 LENALIDOMIDE SPC G Lenalidomide - 25mg 25mg Capsule, hard 87,161,381 L.L
L04AX04 LENOMA G Lenalidomide - 25mg 25mg Capsule, hard 15,343,847 L.L
L04AX04 LENOMA G Lenalidomide - 10mg 10mg Capsule, hard L.L
L04AX04 LENOMA G Lenalidomide - 25mg 25mg Capsule, hard L.L
L04AX04 LENOMA G Lenalidomide - 15mg 15mg Capsule, hard L.L
L01EX08 LENVIMA B Lenvatinib - 10mg 10mg Capsule, hard L.L
L01EX08 LENVIMA B Lenvatinib - 4mg 4mg Capsule, hard L.L
D01AC12 LOMEXIN B Fenticonazole nitrate - 2g/100g 2% Cream 729,154 L.L
D01AE15 LAMISIL B Terbinafine HCl - 10mg/g 1% Cream 616,824 L.L
D01AE15 LAMISIL B Terbinafine HCl - 10mg/g 1% Cream 616,824 L.L
D01AE15 LAMIFEN G Terbinafine HCl - 1% 1% Cream 321,178 L.L
D01AE15 LAMINOX G Terbinafine HCl - 10mg/g 10mg/g Cream 453,067 L.L
D07AB02 LOCOID B Hydrocortisone butyrate - 1mg/g 0.1% Cream 215,015 L.L
D07AB02 LOCOID B Hydrocortisone butyrate - 1mg/g 0.1% Cream 215,015 L.L
D07XC01 LOTRIDERM B Betamethasone (dipropionate) - 0.5mg/g, Clotrimazole - 10mg/g Cream 408,528 L.L
S01ED51 LOPROSTAN G Timolol - 5mg/ml, Latanoprost - 50?g/ml Drops 768,678 L.L
S01EA05 LUMIFY B Brimonidine tartrate - 0.025% Drops solution 1,888,099 L.L
S01EE03 LUMIGAN B Bimatoprost - 0.1mg/ml 0.1mg/ml Drops solution 740,457 L.L
S01EE03 LUMIGAN B Bimatoprost - 0.1mg/ml 0.1mg/ml Drops solution 740,457 L.L
S01XA20 LUBRI-TEARS G Carmellose sodium - 2mg Drops solution 792,867 L.L
S01CA02 LOXTRA G Prednisolone acetate - 2mg/ml, Tetrahydrozoline HCl - 0.4mg/ml, Ofloxacin - 3mg/ml Drops suspension 423,310 L.L
J07CA LANTIGEN B B Streptococcus pneumoniae type 3 (antigenic extracts) - 63.2A.U./ml, Streptococcus pyogenes group A (antigenic extracts) - 126.2A.U./ml, Branhamella catarrhalis (antigenic extracts) - 39.9A.U./ml, Staphylococcus aureus (antigenic extracts) - 79.6A.U./ml, Haemophilus influenzae type b (antigenic extracts) - 50.2A.U./ml, Klebsiella pneumoniae (antigenic extracts) - 39.8A.U./ml Drops suspension 916,501 L.L
S01BA14 LOTEMAX B Loteprednol etabonate - 0.5% 0.5% Drops suspension 1,038,790 L.L
    1
    2
    3
    4
    5
    6
    ...
    10
Sitemap
© Copyrights reserved to Ministry of Public Health 2025